Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Started a GLP‑1 drug like Ozempic or Mounjaro? Here's what you need to know about nutrition (opens in a new tab)

medicalxpress.com · 2026-10-21

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

32 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Source paper

Source layer

The 17 papers the story cites

Source study separated from background citations.

The research anchor for the report.

The literature search

32 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 28 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedGLP-1 medications such as semaglutide and tirzepatide are very effective at managing diabetes, obesity and metabolic or weight-related health conditions, but they can come with gastrointestinal and other side effects, including nutritional deficiencies.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedCompared with placebo, average weight loss is about 6.24 kg higher with semaglutide 1 mg weekly and up to 10.8 kg greater with tirzepatide 15 mg weekly; in longer studies, semaglutide 2.4 mg weekly is associated with about 10.2% body-weight loss and tirzepatide 15 mg with about 14.8%.View evidenceHide evidence

As stated6.24 kg to 10.8 kg more weight loss; 10.2% to 14.8% body-weight loss

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedThe most common side effects reported with GLP-1 use are nausea, diarrhea, vomiting, indigestion and constipation, and side effects may lead people to stop taking the medication, after which weight and some weight-related risk factors can return toward baseline.View evidenceHide evidence

As statednausea in 21% in one review; diarrhea 10%, vomiting 9%, indigestion 9%, constipation 8%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedA team review of 41 studies across 50,000 people found only two studies recorded what people ate in response to GLP-1 medication, and buffet-meal experiments suggested adults ate about 25%–33% less at lunch, with total daily intake reduced by about 3,036 kJ to 3,581 kJ in some studies.View evidenceHide evidence

As stated1,132 kJ less at lunch; 25%–33% less; 3,036 kJ to 3,581 kJ less over a day

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedBecause GLP-1s can reduce food intake enough to trigger rapid weight loss, the article says they increase the risk of malnutrition and nutrient deficiencies such as thiamine deficiency, metabolic acidosis from severe loss of appetite, low magnesium and low blood sugar.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe article advises people taking GLP-1 medications to monitor intake, keep a food diary if needed, aim for a balanced diet with enough protein, fiber, vitamins and minerals, and ask for a dietitian referral if appetite or gut side effects make eating erratic.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, PubMed, Europe PMC · 32 candidate papers

Explore all search results